HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users

Abstract Background Statins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the pharmacological target o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Areej S. Albawa’neh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Nour al dain Marzouka, Lilas Dabaghie, Dana Hamza, Lubna Q. Khasawneh, Virendra Misra, Husam Ouda, Bassam R. Ali
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-04-01
Edice:	Human Genomics
Témata:	Statins New onset type 2 diabetes Pharmacogenetics.
On-line přístup:	https://doi.org/10.1186/s40246-026-00962-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!